Impact News +++ RIOT Platform Q1 preview: Make-or-break earnings as analysts cut bets (SeekingAlpha) +++ RIOT PLATFORMS Aktie -3,25%

INNOCAN Aktie

>INNOCAN Aktienkurs

3.79 EUR +0.3% (TradegateBSX)

Ask: 3.97 EUR / 250 Stück

Bid: 3.72 EUR / 270 Stück

Tagesumsatz: 84 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

INNOCAN Aktie über LYNX handeln

Intraday

1 Jahr

>INNOCAN Performance

1 Woche: -3,9%

1 Monat: -5,4%

3 Monate: -20,4%

6 Monate: -64,3%

1 Jahr: 0%

laufendes Jahr: -10,0%

>INNOCAN Aktie

Name:

INNOCAN PHARMA CORP.

Land:

Kanada

Sektor:

Gesundheit

ISIN/ Wkn:

CA45783P5085 / A41FTP

Symbol/ Ticker:

IP40 (Frankfurt)

Kürzel:

FRA:IP40, ETR:IP40, IP40:GR

Index:

Webseite:

https://innocanpharma.com..

Profil:

InnoCan Pharma Corporation is a pharmaceutical technology company founded in 2018 and headquartered in Calgary, Canada. It specializes in innovative drug delivery platforms that combine cannabidiol (CBD) with other pharmaceutical ingredients to treat..
>Volltext..

Marktkapitalisierung:

16.91 Mio. EUR

Unternehmenswert:

14.21 Mio. EUR

Umsatz:

23.15 Mio. EUR

EBITDA:

-1.03 Mio. EUR

Nettogewinn:

-0.96 Mio. EUR

Gewinn je Aktie:

-0.22 EUR

Schulden:

0.79 Mio. EUR

Liquide Mittel:

5.74 Mio. EUR

Operativer Cashflow:

0.43 Mio. EUR

Bargeldquote:

4.97

Umsatzwachstum:

-14.59%

Gewinnwachstum:

42.14%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

INNOCAN

Letzte Datenerhebung:

29.04.26

>INNOCAN Kennzahlen

Aktien/ Unternehmen:

Aktien: 4.5 Mio. St.

Frei handelbar: 77.34%

Leerverk. Aktien: -

Rückkaufquote: -2.66%

Mitarbeiter: -

Umsatz/Mitarb.: -

Analysten:

Analystenrating: No rating

Kursziel: -

Bewertung:

KGV: -

KGV lG: -

KUV: 0.72

KBV: 3.51

PEG-Ratio: -

EV/EBITDA: -

Rentabilität:

Bruttomarge: 89.94%

Gewinnmarge: -4.17%

Operative Marge: -4.6%

Managementeffizenz:

Gesamtkaprendite: -11.19%

Eigenkaprendite: -20.54%

>INNOCAN Peer Group

Gesundheit, Neurologie/ psychische Behandlung/ Schlaganfälle

>INNOCAN Chart & Kurs - Tradegate

>INNOCAN News

06.04.26 - 12:57	Innocan Pharma Announces Closing of Additional Debenture (PR Newswire)
	HERZLIYA, Israel and CALGARY, AB, April 6, 2026 /PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "Company" or "Innocan") is pleased to announce that it has closed its previously announced offering of an additional debenture of the Company (the......

02.04.26 - 20:12	Innocan Pharma reports FY results (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

31.03.26 - 16:21	Innocan Pharma Announces Offering of an Additional Debenture to Tamar Innovest (PR Newswire)
	HERZLIYA, Israel and CALGARY, AB, March 31, 2026 /PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "Company" or "Innocan") is pleased to announce that it intends to complete an offering of a debenture of the Company (the "Debenture") to its largest......

31.03.26 - 09:03	Innocan Pharma Reports 2025 Financial Results, with Revenues at US $26.6M (PR Newswire)
	HERZLIYA, Israel and CALGARY, AB, March 31, 2026 /PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "Company" or "Innocan"), a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies, is pleased to announce......

16.03.26 - 22:07	Innocan Pharma Announces Closing of a Debenture to its Largest Shareholder, Tamar Innovest (PR Newswire)
	HERZLIYA, Israel and CALGARY, AB, March 16, 2026 /PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "Company" or "Innocan") is pleased to announce that it has closed its previously announced offering of a debenture of the Company (the "Debenture") to its......

11.03.26 - 23:45	Innocan Pharma Announces Offering of a Debenture to its Largest Shareholder, Tamar Innovest (PR Newswire)
	HERZLIYA, Israel and CALGARY, AB, March 11, 2026 /PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "Company" or "Innocan") is pleased to announce that it intends to complete an offering of a debenture of the Company (the "Debenture") to its largest......

27.02.26 - 22:33	FDA Center for Veterinary Medicine Grants Innocan a Fee Waiver in 2026 for the Third Consecutive Time (PR Newswire)
	HERZLIYA, Israel and CALGARY, AB, Feb. 27, 2026 /PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP40) (OTCQB: INNPD) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce that the FDA's Center for Veterinary......

09.02.26 - 17:01	Innocan Pharma gibt Ergebnisse einer randomisierten, verblindeten klinischen Studie mit Hunden bekannt: LPT-CBD ist Placebo bei Schmerzlinderung überlegen (IRW Press)
	Herzliya, Israel und Calgary, Alberta 9. Februar 2026 / IRW-Press / Innocan Pharma Corporation (CSE: INNO) (FWB: IP40) (OTCQB: INNPD) (Innocan oder das Unternehmen), ein Vorreiter auf dem Gebiet der......

09.02.26 - 15:12	Innocan Pharma Announces LPT-CBD demonstrates Pain Relief over Placebo-Results from a randomized blinded clinical study in Dogs (PR Newswire)
	HERZLIYA, Israel and CALGARY, AB, Feb. 9, 2026 /PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP40) (OTCQB: INNPD) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, proudly announces the publication of a research article titled......

27.01.26 - 22:18	Innocan Pharma Corporation plant Listing an der NYSE American Stock Exchange mit gleichzeitigem Emissionsangebot (IRW Press)
	Herzliya, Israel und Calgary, AB 27. Januar 2026 / IRW-Press / Innocan Pharma Corporation (CSE: INNO) (FWB: IP4) (OTCQB: INNPF) (das Unternehmen oder Innocan), ein pharmazeutisches......

27.01.26 - 22:03	Innocan Pharma Corporation Anticipates Listing on the NYSE American Stock Exchange with Concurrent Offering (PR Newswire)
	HERZLIYA, Israel and CALGARY, AB, Jan. 27, 2026 /PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan"), a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies, today announced that,......

02.01.26 - 13:06	Innocan Pharma Corporation plant Listing an der NYSE American Stock Exchange mit gleichzeitigem Emissionsangebot (IRW Press)
	Herzliya, Israel und Calgary, AB - 2. Januar 2026 / IRW-Press / Innocan Pharma Corporation (CSE: INNO) (FWB: IP4) (OTCQB: INNPF) (das Unternehmen oder Innocan), ein pharmazeutisches......

02.01.26 - 13:02	Innocan Pharma Corporation Anticipates Listing on the NYSE American Stock Exchange with Concurrent Offering (PR Newswire)
	HERZLIA, Israel and CALGARY, AB, Jan. 2, 2026 /PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan"), a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies, today announced that it......

10.12.25 - 16:42	Innocan Pharma Announces Public Filing of Amended Registration Statement for Proposed U.S. Public Offering (PR Newswire)
	HERZLIYA, Israel and CALGARY, AB, Dec. 10, 2025 /PRNewswire/ -- Innocan Pharma Corporation ("Innocan" or the "Company") (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) is pleased to announce that, further to its press release of July 23, 2025, it has publicly filed an amendment to its registration......

27.11.25 - 19:54	InnoCan Pharma nach Q3-Zahlen: Kursrückgang überschattet hohe Margen und strategische Pläne (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

27.11.25 - 11:31	Innocan Pharma gibt Finanzergebnisse für 3. Quartal 2025 bekannt mit Umsätzen von 21,6 Mio. USD (IRW Press)
	Herzliya, Israel und Calgary, Alberta 27. November 2025 / IRW-Press / Innocan Pharma Corporation (CSE: INNO) (FWB: IP4) (OTC: INNPF) (das Unternehmen oder Innocan), ein pharmazeutisches......

27.11.25 - 07:36	Innocan Pharma Reports Financial Results for Q3 2025, with Revenues at US $21.6M (PR Newswire)
	HERZLIYA, Israel and CALGARY, AB, Nov. 27, 2025 /PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "Company" or "Innocan"), a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies, is pleased to announce......

24.11.25 - 22:06	Innocan Pharma meldet vielversprechende translationale Evidenz aus einer Schmerzlinderungsstudie zur wiederholten Verabreichung von LPT-CBD an Ziegen (IRW Press)
	Herzliya, Israel und Calgary, Alberta 24. November 2025 / IRW-Press / Innocan Pharma Corporation (CSE: INNO) (FWB: IP40) (OTCQB: INNPD) (Innocan oder das Unternehmen), ein Vorreiter auf dem Gebiet......

24.11.25 - 22:03	Innocan Pharma Announces Promising Translational Evidence from a Pain Relief Study of Repeated LPT-CBD Administration in Goats (PR Newswire)
	HERZLIYA, Israel and CALGARY, Alberta, Nov. 24, 2025 /PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP40) (OTCQB: INNPD) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, proudly announces the publication of a research article titled......

20.11.25 - 22:06	Innocan Pharma berichtet über vielversprechende Ergebnisse aus der Verabreichung von LPT-CBD an Göttinger Minischweine, ein bekanntes Tiermodell in der Arzneimitteltoxikologie (IRW Press)
	Herzliya, Israel und Calgary, Alberta 20. November 2025 / IRW-Press / Innocan Pharma Corporation (CSE: INNO) (FWB: IP40) (OTCQB: INNPD) (Innocan oder das Unternehmen), ein Vorreiter auf dem Gebiet......

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Das Vergessen kann eine große produktive Tat sein. - Hans Arndt

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram